Larox revises full-year 2008 forecasts

Larox revises full-year 2008 forecasts

NEWS/EXCHANGE RATES ITT provides 2009 outlook I TT Corp has issued a full-year 2009 earnings forecast of US$3.60– US4.00 per share, including antic...

79KB Sizes 0 Downloads 29 Views


ITT provides 2009 outlook


TT Corp has issued a full-year 2009 earnings forecast of US$3.60– US4.00 per share, including anticipated restructuring costs. The company expects organic revenue growth to be between -2% and +1% compared with anticipated 2008 revenues. Including the expected negative impact of foreign currency exchange, total revenues are expected to be down 2–6% in 2009. ITT has also reaffirmed its earnings guidance from continuing operations for 2008. Excluding special items, the company is expecting 2008 earnings of US$3.97– US$4.03 per share, which is 22% up on 2007’s results. “Given the challenging global economic environment that has worsened in recent months, we have taken a number of proactive measures to better position the company to weather the anticipated difficult year ahead,” said Steve Loranger, chairman, president and CEO of ITT. “We expect these actions – in addition to our strong balance sheet, continued focus on operational excellence, and positive outlook for the defense segment – will provide stability and help us to perform relatively well in the coming year.” In 2009, ITT is expecting organic revenue in its Fluid Technology segment to decline about 4%, reflecting softening municipal and commercial end markets. In the Motion & Flow Control segment, the company expects 2009 organic revenues to be down

approximately 15%, due in part to projected weakness in automotive, marine and certain industrial end-markets. ITT executive management are recommending a dividend of US$0.85 per share for 2009, which is a 22% increase on 2008’s dividend (see Dividends, page 4). “Our people are executing well against our strategies and staying focused on the customer during this difficult time,” added Loranger. “Our ability to meet our 2008 targets despite significant challenges and recommend a substantial dividend increase is testament to the fundamental strength of ITT, the quality of our global teams, and our long-term confidence in the business.” For further information, visit

Larox revises full-year 2008 forecasts


arox Corp says that its net sales and operating profit (EBIT) for 2008 will increase on 2007 but at a slower rate than expected. The growing economic uncertainty has affected the Finnish company’s customers. As a result Larox received fewer than expected new orders during the fourth quarter of 2008. Larox will publish financial statements for January–December 2008 on 13 February 2009. For further information, visit

Exchange Rates against the US Dollar Date: 15.1.2009 Country Australia

Rate A$1.48

Country Netherlands

Rate 0.75










South Africa



South Korea



China Denmark

NKr6.93 Peso47.20 S$1.49
















India Italy Japan Malaysia


Filtration Industry Analyst

Rs48.79 0.75 ¥90.635 Rt3.58




Editorial Office: Elsevier Limited The Boulevard, Langford Lane Kidlington Oxford OX5 1GB United Kingdom Tel: +44 (0)1865 843695 Fax: +44 (0)1865 843933 Email: [email protected] Web: Editor: Roisin Reidy Production Editor: Lin Lucas Subscription Information An annual subscription to Filtration Industry Analyst includes 12 printed issues and online access for up to 5 users. Prices: 1112 for all European countries & Iran US$1247 for all countries except Europe and Japan ¥147 800 for Japan (Prices valid until 31 December 2009) To subscribe send payment to the address above. Tel: +44 (0)1865 843687/Fax: +44 (0)1865 834971 Email: [email protected], or via Subscriptions run for 12 months, from the date payment is received. Periodicals postage is paid at Rahway, NJ 07065, USA. Postmaster send all USA address corrections to: Filtration Industry Analyst, 365 Blair Road, Avenel, NJ 07001, USA Permissions may be sought directly from Elsevier Global Rights Department, PO Box 800, Oxford OX5 1DX, UK; phone: +44 1865 843830, fax: +44 1865 853333, email: [email protected] You may also contact Global Rights directly through Elsevier’s home page (, selecting first ‘Support & contact’, then ‘Copyright & permission’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: +1 978 750 8400, fax: +1 978 750 4744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: +44 (0)20 7631 5555; fax: +44 (0)20 7631 5500. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher. Address permissions requests to: Elsevier Science Global Rights Department, at the mail, fax and email addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

Printed by Mayfield Press (Oxford) LImited 02207


January 2009